Trump’s nuclear deal with Saudi Arabia puts South Korea’s reactor ambitions on ice

Trump’s nuclear deal with Saudi Arabia puts South Korea’s reactor ambitions on ice

A 30-year US-Saudi civilian nuclear pact that favors American suppliers is squeezing out South Korean firms that spent years courting Riyadh.

The United States just signed a nuclear deal with Saudi Arabia that could reshape the global reactor market for a generation. The problem, if you’re South Korea, is that you spent years trying to be in that deal and now you’re watching from the outside.

President Trump approved a 30-year civilian nuclear cooperation agreement with Saudi Arabia around July 22, 2026. The pact covers reactor construction, technology transfers, and nonproliferation safeguards. It also includes a provision that could allow uranium enrichment on Saudi soil, pending the results of a joint feasibility study.

That last part is significant. Enrichment rights have historically been the most contested piece of any nuclear cooperation agreement. The fact that the US is willing to put it on the table for Saudi Arabia, while other countries have faced stricter terms, is already drawing attention in Seoul.

Who wins and who waits

The deal explicitly prioritizes American companies for reactor construction and technology supply. In English: foreign competitors, including South Korea’s state-backed Korea Electric Power Corporation, face a structural disadvantage in bidding for Saudi nuclear contracts.

Advertisement

KEPCO is not a minor player here. South Korea built its entire nuclear export identity around winning the 2009 UAE contract at Barakah, and has been positioning itself for Saudi projects ever since. That bid to become a major global reactor exporter now runs into a wall of American preference clauses.

Seoul’s Foreign Ministry has confirmed it is actively monitoring how US nuclear policy affects South Korea’s own enrichment negotiations. That’s diplomatic language for “we’re unhappy and watching carefully.”

The tension isn’t just commercial. South Korea has its own ambitions around uranium enrichment capacity, and the US has historically pushed back on those. Watching Washington extend enrichment possibilities to Riyadh while keeping Seoul on a shorter leash creates what South Korean officials are calling a double standard.

The Abraham Accords clause

There’s another layer here that makes this deal unusual. Final approval is explicitly tied to Saudi Arabia normalizing relations with Israel under the framework of the Abraham Accords.

That linkage turns what looks like a commercial nuclear agreement into a foreign policy instrument with three moving parts: US energy companies, Saudi nuclear ambitions, and Middle East diplomacy. If the normalization piece stalls, the entire deal could stall with it.

Saudi Arabia has been pursuing civilian nuclear capability for years. The Kingdom has articulated goals around diversifying its energy mix and reducing domestic oil consumption for power generation, which would free up more crude for export.

What this means for the reactor export market

The global market for new nuclear capacity is genuinely competitive right now. South Korea, France, Russia, China, and the US are all pursuing export contracts with varying degrees of state backing. South Korea has been an aggressive and cost-competitive option, often underbidding European competitors.

KEPCO’s exclusion from the Saudi market, if it holds, removes one of the more commercially significant opportunities available to a non-Western supplier. It also signals that US nuclear cooperation agreements may increasingly come bundled with buy-American conditions, a meaningful shift in how Washington uses the nuclear trade as a geopolitical lever.

The broader question for allies is whether the US is willing to apply consistent standards across its nuclear partnerships, or whether commercial and geopolitical priorities will increasingly drive differentiated treatment. South Korea isn’t the only country asking that question right now.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Trump’s nuclear deal with Saudi Arabia puts South Korea’s reactor ambitions on ice

Trump’s nuclear deal with Saudi Arabia puts South Korea’s reactor ambitions on ice

A 30-year US-Saudi civilian nuclear pact that favors American suppliers is squeezing out South Korean firms that spent years courting Riyadh.

The United States just signed a nuclear deal with Saudi Arabia that could reshape the global reactor market for a generation. The problem, if you’re South Korea, is that you spent years trying to be in that deal and now you’re watching from the outside.

President Trump approved a 30-year civilian nuclear cooperation agreement with Saudi Arabia around July 22, 2026. The pact covers reactor construction, technology transfers, and nonproliferation safeguards. It also includes a provision that could allow uranium enrichment on Saudi soil, pending the results of a joint feasibility study.

That last part is significant. Enrichment rights have historically been the most contested piece of any nuclear cooperation agreement. The fact that the US is willing to put it on the table for Saudi Arabia, while other countries have faced stricter terms, is already drawing attention in Seoul.

Who wins and who waits

The deal explicitly prioritizes American companies for reactor construction and technology supply. In English: foreign competitors, including South Korea’s state-backed Korea Electric Power Corporation, face a structural disadvantage in bidding for Saudi nuclear contracts.

Advertisement

KEPCO is not a minor player here. South Korea built its entire nuclear export identity around winning the 2009 UAE contract at Barakah, and has been positioning itself for Saudi projects ever since. That bid to become a major global reactor exporter now runs into a wall of American preference clauses.

Seoul’s Foreign Ministry has confirmed it is actively monitoring how US nuclear policy affects South Korea’s own enrichment negotiations. That’s diplomatic language for “we’re unhappy and watching carefully.”

The tension isn’t just commercial. South Korea has its own ambitions around uranium enrichment capacity, and the US has historically pushed back on those. Watching Washington extend enrichment possibilities to Riyadh while keeping Seoul on a shorter leash creates what South Korean officials are calling a double standard.

The Abraham Accords clause

There’s another layer here that makes this deal unusual. Final approval is explicitly tied to Saudi Arabia normalizing relations with Israel under the framework of the Abraham Accords.

That linkage turns what looks like a commercial nuclear agreement into a foreign policy instrument with three moving parts: US energy companies, Saudi nuclear ambitions, and Middle East diplomacy. If the normalization piece stalls, the entire deal could stall with it.

Saudi Arabia has been pursuing civilian nuclear capability for years. The Kingdom has articulated goals around diversifying its energy mix and reducing domestic oil consumption for power generation, which would free up more crude for export.

What this means for the reactor export market

The global market for new nuclear capacity is genuinely competitive right now. South Korea, France, Russia, China, and the US are all pursuing export contracts with varying degrees of state backing. South Korea has been an aggressive and cost-competitive option, often underbidding European competitors.

KEPCO’s exclusion from the Saudi market, if it holds, removes one of the more commercially significant opportunities available to a non-Western supplier. It also signals that US nuclear cooperation agreements may increasingly come bundled with buy-American conditions, a meaningful shift in how Washington uses the nuclear trade as a geopolitical lever.

The broader question for allies is whether the US is willing to apply consistent standards across its nuclear partnerships, or whether commercial and geopolitical priorities will increasingly drive differentiated treatment. South Korea isn’t the only country asking that question right now.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.